etodolac has been researched along with Canine Diseases in 9 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days." | 9.12 | Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. ( Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R, 2006) |
| "To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs." | 7.74 | Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). ( Crawford, DA; Fitzgerald, KE; Giuliano, EA; Klauss, G; Martin, SL; Moore, CP; Stuhr, CM; Tyler, JW, 2007) |
| "To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis." | 7.73 | In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. ( Budsberg, SC; Reynolds, LR; Sessions, JK, 2005) |
| "A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days." | 5.12 | Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. ( Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R, 2006) |
| "To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs." | 3.74 | Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). ( Crawford, DA; Fitzgerald, KE; Giuliano, EA; Klauss, G; Martin, SL; Moore, CP; Stuhr, CM; Tyler, JW, 2007) |
| "To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis." | 3.73 | In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. ( Budsberg, SC; Reynolds, LR; Sessions, JK, 2005) |
| "To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs." | 2.73 | Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. ( Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007) |
| " Improvement in force transmission was dosage dependent for the primary outcome measurement (vertical impulse)." | 2.69 | Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. ( Budsberg, SC; Claxton, R; DeCamp, CE; Johnston, SA; Schwarz, PD, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ness, TA | 1 |
| Torres, SM | 1 |
| Kramek, EA | 1 |
| Blauvelt, MM | 1 |
| Stiles, J | 1 |
| Hampshire, VA | 1 |
| Doddy, FM | 1 |
| Post, LO | 1 |
| Koogler, TL | 1 |
| Burgess, TM | 1 |
| Batten, PO | 1 |
| Hudson, R | 1 |
| McAdams, DR | 1 |
| Brown, MA | 1 |
| Sessions, JK | 1 |
| Reynolds, LR | 1 |
| Budsberg, SC | 3 |
| Hanson, PD | 1 |
| Brooks, KC | 1 |
| Case, J | 1 |
| Conzemius, M | 1 |
| Gordon, W | 1 |
| Schuessler, J | 1 |
| Shelley, B | 1 |
| Sifferman, R | 1 |
| Drag, M | 1 |
| Alva, R | 1 |
| Bell, L | 1 |
| Romano, D | 1 |
| Fleishman, C | 1 |
| Klauss, G | 1 |
| Giuliano, EA | 1 |
| Moore, CP | 1 |
| Stuhr, CM | 1 |
| Martin, SL | 1 |
| Tyler, JW | 1 |
| Fitzgerald, KE | 1 |
| Crawford, DA | 1 |
| Luna, SP | 1 |
| Basílio, AC | 1 |
| Steagall, PV | 1 |
| Machado, LP | 1 |
| Moutinho, FQ | 1 |
| Takahira, RK | 1 |
| Brandão, CV | 1 |
| Johnston, SA | 1 |
| Schwarz, PD | 1 |
| DeCamp, CE | 1 |
| Claxton, R | 1 |
4 trials available for etodolac and Canine Diseases
| Article | Year |
|---|---|
Effect of dosing and sampling time on serum thyroxine, free thyroxine, and thyrotropin concentrations in dogs following multidose etodolac administration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Drug Administration Schedule; | 2003 |
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Fem | 2006 |
Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Coagulation; Carbazole | 2007 |
Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dog Diseases; Dogs; Dos | 1999 |
5 other studies available for etodolac and Canine Diseases
| Article | Year |
|---|---|
Warning of an adverse effect of etodolac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Keratoconjunctivitis | 2004 |
Adverse drug event reports at the United States Food And Drug Administration Center for Veterinary Medicine.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Stero | 2004 |
In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis.
Topics: Animals; Carbazoles; Cyclooxygenase Inhibitors; Dinoprostone; Dog Diseases; Dogs; Drug Administratio | 2005 |
Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002).
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac | 2007 |
Long-term temporal evaluation of ground reaction forces during development of experimentally induced osteoarthritis in dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Carbazoles; Dog Diseases; | 2001 |